DAY 1: September 26, 2017
Real World Data for drug development, patient access and life cycle management
Nordic Trial Alliance and conference aims.
Real world data for real world decision making
Adapting a real world data & analytics centers of excellence to meet growing needs across the enterprise.
Pan-Nordic registry collaborations.
Possibilities in analytic medicine: how “big data” can impact the development of new medicines and how regulators better can develop guidelines and give scientific support to the industry.
Health analytics platform – better opportunities for secondary use of health data.
Expanding data possibilities
Chair: Arto Vuori, Development Manager, THL
RWD after RCT, evaluating drugs in daily clinical practice.
Finnish Diabetes type II Study – 6 month’s observation results.
Towards outcome-based risk sharing agreements in hospital and outpatient settings - how to utilize RWD?
From Evidence to Consequence.
The role of public-private partnerships in evidence generation.
DAY 2: September 27, 2017
(Auditorium session) Using RWD and biobanks to drive health innovations
(Parallel breakout session: see end of program)
New iniatives in Finnish biobanks - Digital biobank and joint operator.
Norwegian biobanks for research and innovation – status and future perspectives.
The Swedish biobank infrasctructure- current status and future perspectives.
Real-world data in biobank research - from discovery to feasibility studies.
(Auditorium session) Using RWD and biobanks to drive health innovations cont’d
Chair: BiobankPetri Lehto, Director, Policy and Communication, MSD Finland Oy
Epidemiology in the era of digital data: a view from the pharmaceutical industry.
Generic switching of warfarin and risk of excessive anticoagulation: a Danish nationwide cohort study.
Combining clinical trial data, real world registry data and biobanks: prognostic modelling of CRPC (=Castration-resistant prostate cancer).
Health data for research and HTA purposes: a PPP-program on the lung cancer registry.
Data privacy – General Data Protection Regulation and its implications for research (Parallel breakout session: see end of program)
The EFPIA Perspective on the GDPR
Involving the patient in research “Making Hope Bloom”.
End of conference and next steps
Break-out sessions on September, 27
Farenta Oy: Real world data generation for market access purposes.
Marcin Balcerzak, Head of Research, Farenta Oy
MedEngine Oy and Turku Clinical Research Centre (TurkuCRC): Building RWD-projects in practice.
Tero Ylisaukko-oja, CEO
ESiOR Oy with data from multiple stakeholders.
Erkki Soini, CEO